Pattern of cancer/testis antigen expression in lung cancer patients

  • Authors:
    • Yeong-Dae Kim
    • Hae-Rim Park
    • Myung-Ha Song
    • Dong-Hoon Shin
    • Chang-Hun Lee
    • Min-Ki Lee
    • Sang-Yull Lee
  • View Affiliations

  • Published online on: January 24, 2012     https://doi.org/10.3892/ijmm.2012.896
  • Pages: 656-662
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cancer/testis (CT) antigens represent promising targets for immunotherapy. We investigated the composite expression of 13 CT antigens by RT-PCR in 79 lung cancer tissues and by immunohistochemistry in 22 lung cancer tissues. In the 79 lung cancer tissues, MAGE-3 (42%) was expressed most frequently and followed by NY-SAR-35 (33%), NY-ESO-1 (30%), MAGE-1 (27%), CT-7 (20%), MAGE-4 (19%), LAGE-1 (16%), and MAGE-10 (14%). Twenty-one tissues did not express any of the CT antigens tested, 58 (73%) expressed at least one, 36 (46%) co-expressed two, 24 (30%) co-expressed three, 17 (22%) co-expressed four, 14 (18%) co-expressed five, 8 (10%) co-expressed six, 4 (6%) co-expressed seven and 2 tissues expressed 9 of the 13 examined CT antigens. Expression of CT antigens was significantly associated with age (P<0.001), smoking history (P=0.009), and gender (P=0.001) of patients, whereas no correlation was found between the expression of CT antigens and other clinical factors, such as pT status, pN status, tumor stage, and histology history. The present results show that CT antigens are potential candidates in lung cancer patients for polyvalent immunotherapy.

Introduction

Lung cancer is the major cause of cancer-related mortality worldwide and is also one of the most frequent causes of death in Korea (1). The high mortality of lung cancer generally results from the difficulties in early diagnosis and the lack of effective therapeutic methods. Established therapeutic methods for lung cancer are surgical resection, chemotherapy, and radiotherapy. The results remain unsatisfactory, making it imperative that new diagnostic and therapeutic methods be developed. Immunotherapy is one of the alternative treatments for lung cancer, because various immunotherapies seem to improve the prognosis of patients with lung cancer (2).

An essential condition for the development of effective immunotherapeutic strategies is the existence and identification of tumor specific antigens that are either exclusively or preferentially expressed in malignant compared to normal tissues (3). Human tumor antigens are classified in several categories, including differentiation antigens (4), mutated gene products (5), overexpressed oncogenes (6), and cancer/testis antigens (CT) (7,8).

CT antigens are immunogenic proteins expressed in normal testis and in different types of tumors (3,9). CT antigens are promising candidates for cancer immunotherapy and the identification of novel CT antigens is a prerequisite for the development of cancer vaccines (10,11). CT antigens have previously been isolated by various methods. Examples of CT antigens are the T-cell defined MAGE (12), BAGE (13), and GAGE (14) antigens, as well as SSX-2 (15), NY-ESO-1 (16), SCP-1 (17), CT-7 (8), NY-SAR-35 (18), and NY-TLU-57 (19), all which have been defined using SEREX (the serological identification of antigens by recombinant expression cloning) (20). To date, more than 100 CT antigens have been identified and their expression studied in numerous cancer types (11). Only 19 protein products of CT antigen families have been demonstrated to be able to elicit an immune response in humans (3,11). Though little is known about the biological function of CT antigens, knowledge about their presence in lung cancer tissues can have important implications for the understanding of the biology of both lung cancer and cancer immunity. Previous analysis of the CT antigens revealed that some of them are also expressed in lung cancer (21,22). However, little is known about analysis of a larger panel of CT antigens especially in lung cancer tissues.

The present study analyzes the frequency of expression of 13 CT antigens in 79 lung cancer tissues. The correlation between CT antigen expression patterns and pathological characteristics of lung cancer tissues was also studied.

Materials and methods

Lung cancer tissues

Human tumor tissues were obtained from lung cancer operations performed at the Pusan National University Hospital, Busan, Korea. Analyses were performed on tumor tissue samples of 79 patients with lung cancer confirmed pathologically. The tumor samples consisted of 33 cases of adenocarcinoma, 24 of squamous cell carcinoma, 6 of neuroendocrine carcinoma, 4 of pleomorphic carcinoma, and 12 of others (3 adenosquamous carcinoma, 2 unclassified non-small cell carcinoma, 2 small cell carcinoma, 1 small round cell sarcoma, and 4 metastatic cancers). Among the 79 lung cancer patients from whom tissue samples were obtained, 68 had available records, but 11 did not. Data for the 68 tissues including gender, age, classification of TNM status, and stages were obtained from the clinical and pathological records. Tumor stage and progression were classified according to the International Staging System (23).

Total-RNA extraction from lung cancer tissues

Total cellular RNA was extracted from frozen tissue specimens of 79 lung cancer samples, using TRI Reagent (Molecular Research Center, Inc.). RNA extraction using TRIzol (Invitrogen Life Technologies, Carlsbad, CA), a common protocol, was used. Tumor tissues removed at surgery were snap-frozen and stored at −70°C. Total-RNA was isolated from ~100 mg of each tissue sample using 1 ml TRI Reagent (Molecular Research Center, Inc.), extracted with chloroform, precipitated with isopropyl alcohol, washed with ethanol and re-dissolved in RNase-free water. The amount of isolated RNA was measured by a spectrophotometer (Ultrospec 2000, Pharmacia Biotech) at 260 nm.

Reverse transcription (RT)-PCR

The cDNA preparations used as templates in the RT-PCR reactions were prepared by using 500 ng of total-RNA in conjunction with the SuperScript First Strand Synthesis kit (Invitrogen Life Technologies).

The 13 primer sets for the 13 CT antigens and the lengths of each PCR product are shown in Table I. Each 20 μl PCR mixture consisted of 2 μl cDNA, 0.4 μl of 10 mM dNTP-mix (Solgent), 2 μl of 10X Taq buffer (Solgent), gene specific forward and reverse primers, and 0.2 μl of TaqDNA polymerase (Solgent). For PCR, DNA polymerase activation was performed for 5 min at 94°C, and then amplification was performed in a 96-well Gene Amp PCR System 9700 for 35 cycles as follows: 1 min at 94°C; 1 min at the respective annealing temperature as indicated in Table I; 1 min at 72°C and was concluded with a final extension step of 10 min at 72°C. A 20 μl aliquot of each reaction was size-fractionated on a 1.5% agarose gel, visualized by ethidium bromide staining and assessed for products of the expected size.

Table I

Primers used for RT-PCR.

Table I

Primers used for RT-PCR.

GenesPrimer sequencesAnnealing temperature (°C)References
NY-SAR-35F: 5′-CTTGGTGCGATCAGCCTTAT-3′
R: 5′-TTGATGCATGAAAACAGAACTC-3′55(18)
SCP-1F: 5′-GTACAGCAGAAAGCAAGCAACTGAATG-3′
R: 5′-GAAGGAACTGCTTTAGAATCCAATTTCC-3′60(18)
SSX-1F: 5′-CTAAAGCATCAGAGAAGAGAAGC-3′
R: 5′-AGATCTCTTATTAATCTTCTCAGAAA-3′60(18)
SSX-2F: 5′-GTGCTCAAATACCAGAGAAGATC-3′
R: 5′-TTTTGGGTCCAGATCTCTCGTG-3′65(18)
SSX-4F: 5′-AAA TCGTCTATGGTATATGAAGCT-3′
R: 5′-GGGTCGCTGATCTCTTCATAAAC-3′60(18)
MAGE-1F: 5′-GCTGGAACCCTCACTGGGTTGCC-3′
R: 5′-CGGCCGAAGGAACCTGACCCAG-3′62(18)
MAGE-3F: 5′-GAAGCCGGCCCAGGCTCG-3′
R: 5′-GGAGTCCTCATAGGATTGGCT-3′62(18)
MAGE-4F: 5′-GAGCAGACAGGCCAACCG-3′
R: 5′-AAGGACTCTGCGTCAGGC-3′65(18)
MAGE-10F: 5′-GGAACCCCTCTTTTCTACAGAC-3′
R: 5′-TCCTCTGGGGTGCTTGGTATTA-3′60(18)
CT-7F: 5′-GACGAGGATCGTCTCAGGTCAGC-3′
R: 5′-ACATCCTCACCCTCAGGAGGG-3′60(18)
NY-TLU-57F: 5′-TCATATGCCTAGCTCTGTCAAAAG-3′
R: 5′-TCCCGGGTCTGGCATCAATAAAAT-3′60(19)
NY-ESO-1F: 5′-CCCCACCGCTTCCCGTG-3′
R: 5′-CTGGCCACTCGTGCTGGGA-3′60(19)
LAGE-1F: 5′-CTGCGCAGGATGGAAGGTGCCCC-3′
R: 5′-GCGCCTCTGCCCTGAGGGAGC-3′62(19)

[i] Primers were referenced from http://www.cancerimmunity.org/CTdatabase.

Immunohistochemistry

The M3H67 monclonal antibody (to MAGE-3) was obtained from the Ludwig Institute for Cancer Research, New York Branch at the Memorial-Kettering Cancer. Immunohistochemical staining was performed according to the previously report (24). Briefly, paraffin sections were applied to slides for immunohistochemistry and heated for 20 min at 60°C. Slides were deparaffinized and rehydrated in a series of graded alcohols. Antigen retrieval was performed by placing the slides in TE buffer (pH 9.0) and heating for 40 min in a steamer and then allowed to cool. M3H67 of 1.0 μg/ml antibody was incubated for 1 h in a room temperature. Sections were washed with PBS for 20 min and then slides were incubated with a secondary antibody for 1 h at 37°C, washed and incubated with the avidin-biotin complex system for 1 h at 37°C. Sections were sequentially washed and then slides were counterstained with hematoxylin. The extent of staining was estimated and graded as follows: focal staining of single cells or small clusters (>50% total) was considered positive, whereas focal staining of single cells or small clusters (<50% total) was considered negative.

Statistical analysis

Statistical analysis was performed with the SPSS program (version 11.5; SPSS Inc., Chicago, IL). Pearson χ2 test was used to compare the correlation between disease stage, grade, and CT antigen expression. Statistical significance was accepted at P<0.05.

Results

Expression of CT antigens in lung cancer tissues

Expression of the 13 CT antigens (NY-SAR-35, SCP-1, SSX-1, SSX-2, SSX-4, MAGE-1, MAGE-3, MAGE-4, MAGE-10, CT-7, NY-TLU-57, NY-ESO-1 and LAGE-1) was assessed by RT-PCR in 79 lung cancer tissue samples. Representative RT-PCR results from lung cancer tissues are shown in Fig. 1. The most frequently expressed CT antigen was MAGE-3 (33/79, 42%), followed by NY-SAR-35 (26/79, 33%), NY-ESO-1 (24/79, 30%), MAGE-1 (21/79, 27%), CT-7 (16/79, 20%), MAGE-4 (15/79, 19%), LAGE-1 (13/79, 16%), MAGE-10 (11/79, 14%), SSX-2 (3/79, 4%), SSX-4 (2/79, 3%), NY-TLU-57 (1/79, 1%), SCP-1 (0/79, 0%) and SSX-1 (0/79, 0%) (Fig. 2). In previous studies, the MAGE-3 antigen was expressed in between 30–50% of the lung cancer tissues examined (25,26). In the present study, MAGE-3 was detected in 42% of all lung cancer tissue samples. Among the 58 CT antigen-positive lung cancer tissue samples, MAGE-3 and NY-SAR-35 were respectively expressed in 57 and 45% of the samples. These findings indicate that MAGE-3 and NY-SAR-35 are attractive targets for antigen-specific immunotherapy in Korean lung cancer patients.

Co-expression of multiple CT antigen mRNA in lung cancer tissues

The percentages of co-expressed CT antigens in lung cancer tissues are shown in Fig. 3. Fifty-eight of 79 lung cancer tissues (73%) were found to express at least one of the CT antigens, whereas 21 (26%) did not express CT antigens. Thirty-six cases (45%) expressed more than two CT antigens and three or more CT antigens were expressed in 24 cases (30%). Seventeen specimens expressed ≥4 (21%), 14 specimens expressed ≥5 (18%), 8 cases ≥6 (10%), 4 cases ≥7 (5%), 2 cases ≥8 (3%) and two tissues co-expressed 9 antigens. From these data, it becomes evident that 73% of our patients with lung cancer tissues would be eligible for antigen specific immunotherapeutic approaches with at least one CT antigen.

Relationship between cancer/testis antigen expression and tumor characteristics

The characteristics of the patients are summarized in Table I. The following data of the patients were entered in a prospective database: there were 49 men and 19 women, with ages ranging from 37 to 80 years (>60 vs. ≤ 60 years of ages); 22 patients were non-smokers, and 46 patients were smokers; there were 26 patients with pT1, 35 with pT2 and 7 with pT3; there were 54 patients with pN0 or pN1 and 14 patients with pN2 or pN3. In addition, there were 50 patients with clinical stage I or II and 18 with clinical stage III or IV at the time of diagnosis. We then investigated the possible correlation between CT antigen expression and these clinical variables (Table II). The data included patients whose tumors expressed at least one CT antigen. CT antigen expression was found to be associated with male gender (P=0.001), age (P<0.001), and smoking history (P=0.009). On the other hand, no correlation was detected between CT antigen expression and other clinical factors, such as pT status, pN status, tumor stages, and histology history. Between the adenocarcinoma and squamous cell carcinoma samples, expression of CT antigens in adenocarcinoma samples had a tendency to be more frequent than in squamous cell carcinoma. In addition, expression of individual MAGE-3 (P=0.003) and NY-SAR-35 (P=0.036) were found to be associated with squamous cell carcinoma and adenocarcinoma, respectively (Table III).

Table II

Summary of patient characteristics and expression of CT antigens.

Table II

Summary of patient characteristics and expression of CT antigens.

CharacteristicNumber of patientsNumber of patients expressing CT gene mRNAsP-value
Age
 >602911<0.001
 ≤603935
Gender
 Male49420.001
 Female198
Smoking history
 No22110.009
 Yes4638
pT status
 pT126190.678
 pT23525
 pT3 and 476
pN status
 pN0 and 154390.295
 pN 2 and 31411
Pathological stage
 I and II50360.635
 I and IV1814
Histology
 Adenocarcinoma33250.55
 Squamous cell carcinoma2416
 Neuroendocrine carcinoma66
 Carcinoma with pleomorphic43
 Others128

Table III

The expression of CT antigens according to the histological classification of lung cancer tissues.

Table III

The expression of CT antigens according to the histological classification of lung cancer tissues.

Number of patients expressing a CT gene

Histological typeNo. of patientsNY-SAR35SCP-1SSX-1SSX-2SSX-4MAGE-1MAGE-3MAGE-4MAGE-10CT-7NY-TLU57NY-ESO-1LAGE-1
Adenocarcinoma3310001148336084
Squamous cell carcinoma2440010713944073
Neuroendocrine carcinoma64001045123133
Sarcomatoid carcinoma43000134122030
Others124000032001023
P-valuea0.0360.0100.0030.0490.0940.2170.2360.072

a Statistical analysis was performed for the CT antigen groups in which >5 specimens were positive.

MAGE-3 protein expression

Among the 79 lung cancer tissue specimens, 22 lung carcinoma samples from which sufficient material was available were investigated for the expression of the frequently expressed MAGE-3 protein by immunohistochemistry. Representative immunohistochemistry results of lung cancer tissues with the mAb MAGE-3 are shown in Fig. 4. Expression of MAGE-3 protein was found in 12 of 22 tumor samples (55%) while MAGE-3 mRNA expression was detected in 10/22 tumor samples (45%). Expression of MAGE-3 antigen was observed in 7 of 10 MAGE-3 RT-PCR-positive tumor samples. We observed a correlation between the expression of MAGE-3 protein and the histological type of lung cancer tissues. The MAGE-3 protein was expressed in 8 of 10 squamous cell carcinomas as compared with 3 of 10 adenocarcinomas.

Discussion

CT antigens are immunogenic proteins expressed in normal testis and in different types of tumors. Because of their tissue-restricted expression, CT antigens are ideal candidates for antigen-specific cancer immunotherapy. In general, CT antigens are expressed in 20–40% of specimens from a given tumor type (3). The present study was undertaken to evaluate the expression of CT antigens (NY-SAR-35, SCP-1, SSX-1, SSX-2, SSX-4, MAGE-1, MAGE-3, MAGE-4, MAGE-10, CT-7, NY-TLU57, NY-ESO-1, and LAGE-1) in lung cancer tissues. Moreover, the prognostic role of CT antigen expression and their correlation with a number of clinical pathological parameters were examined. A number of studies have investigated the mRNA expression patterns of individual CT antigens in lung cancer (19,25,27,28). In this study, the SEREX-defined (33% NY-SAR-35 and 30% NY-ESO-1) and the CTL-defined (42% MAGE-3 and 27% MAGE-1) antigens were the most frequently expressed in lung cancer tissues. As MAGE-3, NY-SAR-35, NY-ESO-1 and MAGE-1 were expressed with a high percentage and specificity in lung cancer tissues, their products might be ideal for antigen targets for lung cancer immunotherapy (Fig. 2).

In addition, 58 of 79 lung cancer tissue specimens (73%) were found to express at least one of the CT antigens. According to our results, 73% of our lung cancer patients would be eligible for specific immunotherapeutic approaches with at least one CT antigen. A possibility for the high observation frequency of CT antigen expression in lung cancer tissues could be due to the characteristics of the patients. These results indicate that expression of CT antigens was significantly associated with the age and gender of the patients, whereas no significant correlation was detected between CT antigen expression and other clinical factors such as pT status, pN status, and tumor stages (Table II). In this study, the differences in the expression of CT antigens in 79 lung cancer tissues cannot be ascribed to the characteristics of the patients, but rather reveal intrinsic differences in lung cancer tissues.

The highly homologous NY-ESO-1 and LAGE-1 (94%, nucleotide identity and 88% amino acid identity) are highly immunogenic, and a CTL response to an immunodominant, HLA-A2-restricted NY-ESO-1/LAGE-1 epitope can commonly be detected in cancer patients (29,30). We compared the expression of NY-ESO-1 and LAGE-1 in tissues from lung cancer patients by RT-PCR (Figs. 2 and 3). NY-ESO-1 gene expression was detected in 24/79 (30%) more frequently than in two previous reports, in which NY-ESO-1 was detected in 2/12 (17%) (16) and 3/15 (20%) (31) lung cancer tissues of Caucasian origin. LAGE-1 gene expression was detected in 13/79 (16%) specimens, less frequently than in a previous report (31) in which it was detected in 5/15 (33%) cases. Of the 79 lung cancer tissues, 24/79 (30%) were NY-ESO-1-positive by RT-PCR and 13/79 (16%) were LAGE-1 positive by RT-PCR. The expression of either NY-ESO-1 or LAGE-1 antigens was observed in 29 of 79 (37%) of lung cancer tissue specimens. These results suggested that NY-ESO-1 and LAGE-1 represent targets for immunotherapy in a significant proportion of patients with lung cancer.

Of particular interest was NY-SAR-35, which represents a CT antigen as it appears to be a rare example of a cell surface antigen (19), which was highly expressed in lung cancer tissues. Expression of NY-SAR-35 was found in 33% of all lung cancer tissues. NY-SAR-35 was detected in 45% of 58 CT antigen-positive lung cancer tissues. Recently, we found that treatment with 5-aza-CdR can induce the expression of NY-SAR-35, and that transcriptional silencing of NY-SAR-35 is caused by hypermethylation of its promoter (32). These findings indicated that NY-SAR-35 is an attractive target for antigen-specific immunotherapy in lung cancer and that treatment with demethylating agents, in combination with immunotherapy, could be a useful therapeutic strategy for modulating the antigen expression.

To confirm the existence of MAGE-3 protein expression, 22 lung carcinoma samples from which sufficient material was available were immunohistochemically stained by a specific MAGE-3 monoclonal antibody. Similarly to our previous study (24), we found a correlation with frequent expression of MAGE-3 protein and the histological type of squamous cell carcinomas. The MAGE-3 protein was expressed in 8 of 10 squamous cell carcinomas as compared with 3 of 10 adenocarcinomas. Expression of MAGE-3 protein was demonstrated in 7 of 10 MAGE-3 RT-PCR-positive tumor samples. These results indicate the discordance between RT-PCR and immunohistochemistry positivity. As a note of caution, however, one should keep in mind that MAGE-3 at the protein level may not be detected in all cases expressing the respective mRNA. Whether this is due to a lower sensitivity of the detection method used (immunohistochemistry using CT antigen-specific antibodies) or whether the mRNA is not translated into protein cannot be determined at this point (27,33).

From the data of our study, a high proportion (58/79, 73%) of lung cancer tissues was positive for at least one of these 13 CT antigens as targets will greatly increase the number of candidates for CT antigen-based lung cancer immunotherapy. However, our results showed no expression of CT antigens in 27% (22/79) of lung cancer tissues. For these patients, it is necessary to screen other CT antigens or tumor-specific antigens serving as immune targets for lung cancer tissue immunotherapy. In conclusion, this study demonstrated that lung cancer tissues frequently express CT antigens and a high percent express more than one CT antigen, suggesting that CT antigens are potential candidates for polyvalent immunotherapy.

Acknowledgements

This study was supported by the Medical Research Institute Grant (2006–23), Pusan National University.

References

1 

DM ParkinF BrayJ FerlayP PisaniGlobal cancer statistics, 2002CA Cancer J Clin5574108200510.3322/canjclin.55.2.74

2 

LJ OldCancer vaccines 2003: opening addressCancer Immun3Suppl 2S12003

3 

MJ ScanlanAJ SimpsonLJ OldThe cancer/testis genes: review, standardization, and commentaryCancer Immun41200414738373

4 

PG CoulieV BrichardA Van PelT WolfelJ SchneiderC TraversariS MatteiE De PlaenC LurquinJP SzikoraA new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomasJ Exp Med1803542199410.1084/jem.180.1.358006593

5 

S LabrecqueN NaorD ThomsonG MatlashewskiAnalysis of the anti-p53 antibody response in cancer patientsCancer Res533468347119938339249

6 

ML DisisE CalenoffG McLaughlinAE MurphyW ChenB GronerM JeschkeN LydonE McGlynnRB LivingstonExistent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancerCancer Res54162019947505195

7 

T BoonPG CoulieB Van den EyndeTumor antigens recognized by T cellsImmunol Today18267268199710.1016/S0167-5699(97)80020-59190110

8 

YT ChenAO GureS TsangE StockertE JagerA KnuthLJ OldIdentification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line libraryProc Natl Acad Sci USA9569196923199810.1073/pnas.95.12.69199618514

9 

AJ SimpsonOL CaballeroA JungbluthYT ChenLJ OldCancer/testis antigens, gametogenesis and cancerNat Rev Cancer5615625200510.1038/nrc166916034368

10 

RB ParmigianiF BettoniMD VibranovskiMH LopesWK MartinsIW CunhaFA SoaresAJ SimpsonSJ de SouzaAA CamargoCharacterization of a cancer/testis (CT) antigen gene family capable of eliciting humoral response in cancer patientsProc Natl Acad Sci USA1031806618071200610.1073/pnas.060885310317114284

11 

OL CaballeroYT ChenCancer/testis (CT) antigens: potential targets for immunotherapyCancer Sci10020142021200910.1111/j.1349-7006.2009.01303.x19719775

12 

P van der BruggenC TraversariP ChomezC LurquinE De PlaenB Van den EyndeA KnuthT BoonA gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanomaScience254164316471991

13 

P BoelC WildmannML SensiR BrasseurJC RenauldP CoulieT BoonP van der BruggenBAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytesImmunity2167175199510.1016/S1074-7613(95)80053-07895173

14 

B Van den EyndeO PeetersO De BackerB GauglerS LucasT BoonA new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanomaJ Exp Med1826896981995

15 

O TureciU SahinI SchobertM KoslowskiH ScmittHJ SchildF StennerG SeitzHG RammenseeM PfreundschuhThe SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40Cancer Res564766477219968840996

16 

YT ChenMJ ScanlanU SahinO TureciAO GureS TsangB WilliamsonE StockertM PfreundschuhLJ OldA testicular antigen aberrantly expressed in human cancers detected by autologous antibody screeningProc Natl Acad Sci USA9419141918199710.1073/pnas.94.5.19149050879

17 

O TureciU SahinC ZwickM KoslowskiG SeitzM PfreundschuhIdentification of a meiosis-specific protein as a member of the class of cancer/testis antigensProc Natl Acad Sci USA9552115216199810.1073/pnas.95.9.52119560255

18 

SY LeeY ObataM YoshidaE StockertB WilliamsonAA JungbluthYT ChenLJ OldMJ ScanlanImmunomic analysis of human sarcomaProc Natl Acad Sci USA10026512656200310.1073/pnas.043797210012601173

19 

SY LeeB WilliamsonOL CaballeroYT ChenMJ ScanlanG RitterCV JongeneelAJ SimpsonLJ OldIdentification of the gonad-specific anion transporter SLCO6A1 as a cancer/testis (CT) antigen expressed in human lung cancerCancer Immun413200415546177

20 

U SahinO TureciH SchmittB CochloviusT JohannesR SchmitsF StennerG LuoI SchobertM PfreundschuhHuman neoplasms elicit multiple specific immune responses in the autologous hostProc Natl Acad Sci USA921181011813199510.1073/pnas.92.25.118108524854

21 

K TajimaY ObataH TamakiM YoshidaYT ChenMJ ScanlanLJ OldH KuwanoT TakahashiT MitsudomiExpression of cancer/testis (CT) antigens in lung cancerLung Cancer422333200310.1016/S0169-5002(03)00244-714512184

22 

JR TsaiIW ChongYH ChenMJ YangCC SheuHC ChangJJ HwangJY HungSR LinDifferential expression profile of MAGE family in non-small-cell lung cancerLung Cancer56185192200710.1016/j.lungcan.2006.12.00417208331

23 

LH SobinP HermanekRV HutterTNM classification of malignant tumors. A comparison between the new (1987) and the old editionsCancer6123102314198810.1002/1097-0142(19880601)61:11%3C2310::AID-CNCR2820611127%3E3.0.CO;2-X3284634

24 

SH KimS LeeCH LeeMK LeeYD KimDH ShinKU ChoiJY KimY Park doMY SolExpression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltrationLung187401411200910.1007/s00408-009-9181-319795170

25 

P WeynantsB LetheF BrasseurM MarchandT BoonExpression of mage genes by non-small-cell lung carcinomasInt J Cancer56826829199410.1002/ijc.29105606128119772

26 

S LucasC De SmetKC ArdenCS ViarsB LetheC LurquinT BoonIdentification of a new MAGE gene with tumor-specific expression by representational difference analysisCancer Res5874375219989485030

27 

C FischerF GudatP StulzC NoppenC SchaeferP ZajacM TrutmannT KocherM ZuberF HarderHigh expression of MAGE-3 protein in squamous-cell lung carcinomaInt J Cancer7111191121199710.1002/(SICI)1097-0215(19970611)71:6%3C1119::AID-IJC34%3E3.0.CO;2-59185722

28 

MJ ScanlanNK AltorkiAO GureB WilliamsonA JungbluthYT ChenLJ OldExpression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9Cancer Lett150155164200010.1016/S0304-3835(99)00385-710704737

29 

D RimoldiV Rubio-GodoyV DutoitD LienardS SalviP GuillaumeD SpeiserE StockertG SpagnoliC ServisEfficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanomaJ Immunol16572537261200010.4049/jimmunol.165.12.725311120859

30 

F van RheeSM SzmaniaF ZhanSK GuptaM PomtreeP LinRB BatchuA MorenoG SpagnoliJ ShaughnessyNY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responsesBlood10539393944200515671442

31 

B LetheS LucasL MichauxC De SmetD GodelaineA SerranoE De PlaenT BoonLAGE-1, a new gene with tumor specificityInt J Cancer76903908199810.1002/(SICI)1097-0215(19980610)76:6%3C903::AID-IJC22%3E3.0.CO;2-19626360

32 

JH ParkMH SongCH LeeMK LeeYM ParkL OldSY LeeExpression of the human cancer/testis antigen NY-SAR-35 is activated by CpG island hypomethylationBiotechnol Lett3310851091201110.1007/s10529-011-0559-y21318630

33 

A MischoB KubuschokK ErtanKD PreussB RomeikeE RegitzC SchormannD de BruijnA WadleF NeumannProspective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancerInt J Cancer118696703200610.1002/ijc.2135216094643

Related Articles

Journal Cover

April 2012
Volume 29 Issue 4

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kim Y, Park H, Song M, Shin D, Lee C, Lee M and Lee S: Pattern of cancer/testis antigen expression in lung cancer patients . Int J Mol Med 29: 656-662, 2012.
APA
Kim, Y., Park, H., Song, M., Shin, D., Lee, C., Lee, M., & Lee, S. (2012). Pattern of cancer/testis antigen expression in lung cancer patients . International Journal of Molecular Medicine, 29, 656-662. https://doi.org/10.3892/ijmm.2012.896
MLA
Kim, Y., Park, H., Song, M., Shin, D., Lee, C., Lee, M., Lee, S."Pattern of cancer/testis antigen expression in lung cancer patients ". International Journal of Molecular Medicine 29.4 (2012): 656-662.
Chicago
Kim, Y., Park, H., Song, M., Shin, D., Lee, C., Lee, M., Lee, S."Pattern of cancer/testis antigen expression in lung cancer patients ". International Journal of Molecular Medicine 29, no. 4 (2012): 656-662. https://doi.org/10.3892/ijmm.2012.896